Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03399552 · OUTCOME

Overall Response Rate

Stereotactic Body Radiation Therapy and Avelumab Immunotherapy for Treatment of Malignant Mesothelioma · Source last updated 2023-10-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
3 years

What was measured

defined by modified RECIST 1.1 for mesothelioma

Groups in this outcome

Avelumab

The treatment will consist of avelumab as well as a short course of Stereotactic Body Radiation Therapy

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Avelumab15

Reported measurements

Source class 1

Clinical Progression

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Avelumab2Not reportedNot reportedNot reportedNot reported

Stable Disease

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Avelumab8Not reportedNot reportedNot reportedNot reported

Partial Response

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Avelumab1Not reportedNot reportedNot reportedNot reported

Non-evaluable

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Avelumab4Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        2
      title
      Clinical Progression
    2. measurements
      1. group Id
        OG000
        value
        8
      title
      Stable Disease
    3. measurements
      1. group Id
        OG000
        value
        1
      title
      Partial Response
    4. measurements
      1. group Id
        OG000
        value
        4
      title
      Non-evaluable
denoms
  1. counts
    1. group Id
      OG000
      value
      15
    units
    Participants
description
defined by modified RECIST 1.1 for mesothelioma
groups
  1. description
    The treatment will consist of avelumab as well as a short course of Stereotactic Body Radiation Therapy
    id
    OG000
    title
    Avelumab
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
3 years
title
Overall Response Rate
type
PRIMARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice